160 related articles for article (PubMed ID: 12512392)
1. Heat shock protein and proteasome targeting agents.
Takimoto CH; Diggikar S
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1269-85. PubMed ID: 12512392
[TBL] [Abstract][Full Text] [Related]
2. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Tsuruo T; Naito M; Tomida A; Fujita N; Mashima T; Sakamoto H; Haga N
Cancer Sci; 2003 Jan; 94(1):15-21. PubMed ID: 12708468
[TBL] [Abstract][Full Text] [Related]
3. [Heat shock protein 90: novel target for cancer therapy].
Chen Y; Ding J
Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein inhibitor shows antitumor activity.
Dunn FB
J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
[No Abstract] [Full Text] [Related]
5. The Hsp90 chaperone complex as a novel target for cancer therapy.
Goetz MP; Toft DO; Ames MM; Erlichman C
Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
Ivy PS; Schoenfeldt M
Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
[No Abstract] [Full Text] [Related]
7. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
8. Cancer: the rules of attraction.
Neckers L; Lee YS
Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
[No Abstract] [Full Text] [Related]
9. Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.
Ochel HJ; Eichhorn K; Gademann G
Cell Stress Chaperones; 2001 Apr; 6(2):105-12. PubMed ID: 11599571
[No Abstract] [Full Text] [Related]
10. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
11. Altered states: selectively drugging the Hsp90 cancer chaperone.
Workman P
Trends Mol Med; 2004 Feb; 10(2):47-51. PubMed ID: 15106614
[TBL] [Abstract][Full Text] [Related]
12. The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70.
Fisher EA; Zhou M; Mitchell DM; Wu X; Omura S; Wang H; Goldberg AL; Ginsberg HN
J Biol Chem; 1997 Aug; 272(33):20427-34. PubMed ID: 9252351
[TBL] [Abstract][Full Text] [Related]
13. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
Bagatell R; Paine-Murrieta GD; Taylor CW; Pulcini EJ; Akinaga S; Benjamin IJ; Whitesell L
Clin Cancer Res; 2000 Aug; 6(8):3312-8. PubMed ID: 10955818
[TBL] [Abstract][Full Text] [Related]
14. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
15. Protein chaperones as anticancer therapy targets.
Sausville E
Clin Adv Hematol Oncol; 2004 Feb; 2(2):92-3. PubMed ID: 16163168
[No Abstract] [Full Text] [Related]
16. Therapeutic and diagnostic implications of Hsp90 activation.
Kamal A; Boehm MF; Burrows FJ
Trends Mol Med; 2004 Jun; 10(6):283-90. PubMed ID: 15177193
[TBL] [Abstract][Full Text] [Related]
17. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
18. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
Nimmanapalli R; O'Bryan E; Bhalla K
Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
[TBL] [Abstract][Full Text] [Related]
19. [Hsp90: how a chaperone becomes a pharmacological target].
Jacquemin-Sablon A
Bull Cancer; 2003 Nov; 90(11):935-6. PubMed ID: 14706894
[No Abstract] [Full Text] [Related]
20. Hsp90 inhibitors in the clinic.
Pacey S; Banerji U; Judson I; Workman P
Handb Exp Pharmacol; 2006; (172):331-58. PubMed ID: 16610366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
